|
![]() |
|
|
Pioglitazone
drug data and news
Pioglitazone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Pioglitazone | ||
| Brand Names/Synonyms | AD-4833; Actos; Actost; CHEMBANK3906; Pioglitazona [Inn-Spanish]; Pioglitazone; Pioglitazone Hydrochloride; Pioglitazone [Ban:Inn]; Pioglitazonum [Inn-Latin] | ||
| Indication | Treatment of Type II diabetes mellitus | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent. | ||
| Mechanism Of Action | Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone enhances tissue sensitivity to insulin. | ||
| Pioglitazone News (When available) |
Pioglitazone Has Cholesterol Advantages Versus Rosiglitazone in ... May 2, 2006 Higher Risk Patients Benefit More After Conversion from ... May 3, 2006 ERRATUM: Higher Risk Patients Benefit More After Conversion from ... May 5, 2006 Takeda Eyeing Prescription Drug Sales of 1.4 Tril. Yen By FY 2010 May 11, 2006 Adverse Events Related to Muraglitazar Use in Diabetes May 2, 2006 Takeda Announces "2006-2010 Medium-Term Management Plan" - Growth ... May 11, 2006 Women Gain More Weight Than Men When Taking Thiazolidinedione ... May 3, 2006 Adverse Events Related to Muraglitazar Use in Diabetes—Reply May 2, 2006 Lilly Reports Q1 EPS of $.77, or 13% Growth Apr 20, 2006 Japan's Takeda, Eli Lilly end joint sales of diabetes drug in US Apr 20, 2006 ABL Bio Technologies launches Invia Health Apr 20, 2006 ABL Biotech's pharma division Apr 29, 2006 Newer Diabetic Meds Cost More, But Users Have Fewer Hospital ... Apr 28, 2006 Zydus Cadila files IND application for NME - ZYH2 Apr 24, 2006 | ||
| Dosage Forms | Oral tablets | ||
| Drug_Category | Hypoglycemic Agents; Thazolidinediones; ATC:A10BG03 | ||
| Absorption | Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption. | ||
| Interactions |
-->Interactions for Pioglitazone: In vivo drug-drug interaction studies have suggested that pioglitazone may be a weak inducer of CYP 450 isoform 3A4 substrate. | ||
| Toxicity | Hypogycemia; LD50=mg/kg (orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione | ||
| Chemical Formula | C19H20N2O3S | ||
| Molecular Weight | 356.44 g/mol | ||
| Smiles String | CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 | ||
| Melting Point | 183-184°C | ||
| Water Solubility | mg/mL | ||
| State | odorless white crystalline powder | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 3-7 hours | ||
| Protein Binding [%] | > 99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Pioglitazone.html http://www.rxlist.com/cgi/generic2/pioglit.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00653 | ||
| CAS Registry Number | 111025-46-8 | ||
| KEGG Compound ID | C07675 | ||
| PubChem ID | SID:9877 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2242573 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |